Effect of cardiovascular comorbidities on the survival patients with stage I and II non-small-cell lung cancer

D. Bursac, N. Secen, D. Sazdanic-Velikic, G. Stojanovic, A. Tepavac, Z. Lozanov-Crvenkovic (Sremska Kamenica, Novi Sad, Republic Of Serbia)

Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer
Session: Instructive clinical aspects of lung cancer
Session type: Thematic Poster Session
Number: 2819

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Bursac, N. Secen, D. Sazdanic-Velikic, G. Stojanovic, A. Tepavac, Z. Lozanov-Crvenkovic (Sremska Kamenica, Novi Sad, Republic Of Serbia). Effect of cardiovascular comorbidities on the survival patients with stage I and II non-small-cell lung cancer. Eur Respir J 2011; 38: Suppl. 55, 2819

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Treatment tolerance and survival in elderly patients with stage IV non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology
Year: 2019


Survival of patients operated for stage I non-small-cell lung cancer
Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology
Year: 2008


Analysis of prognostic factors in patients with stage IIIB, IV non-small cell lung cancer
Source: Annual Congress 2010 - Staging of lung cancer
Year: 2010


Effect of comorbidity on the prognosis of non-small cell lung cancer
Source: Eur Respir J 2006; 28: Suppl. 50, 385s
Year: 2006

Prognostic factors affecting survival in advanced non-small cell lung cancer patients
Source: Eur Respir J 2004; 24: Suppl. 48, 75s
Year: 2004

Effects of prognostic factors on survival of the patients of non-small cell lung cancer
Source: Eur Respir J 2005; 26: Suppl. 49, 326s
Year: 2005

Prognostic factors in patients with resected pathologic stage I and II nonsmall cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 269s
Year: 2002

Survival impact of surgery in the treatment of stage IIIB-IVA non-small cell lung cancer
Source: International Congress 2018 – Lung cancer: personalised medicine
Year: 2018


Impacts of multi and specific co-morbidities on the survival of non-surgical non-small cell lung cancer
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012

Effects of pretreatment prognostic factors and treatment on survival in advanced nonsmall cell lung cancer
Source: Eur Respir J 2003; 22: Suppl. 45, 431s
Year: 2003

Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness
Year: 2019


A retrospective analysis of risk factors for Durvalumab related interstitial lung disease after chemoradiotherapy in Stage III NSCLC
Source: Virtual Congress 2020 – Localised non-small cell lung cancer
Year: 2020


Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer
Source: Eur Respir J, 51 (5) 1702431; 10.1183/13993003.02431-2017
Year: 2018



Two-stage treatment of non-small cell lung cancer (NSCLC) in patients with severe coronary heart disease.
Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology
Year: 2019

Validity of predictive estimate by physicians of the survival of patients with recently diagnosed stages IIIB and IV non-small cells lung cancer (NSCLC)
Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology
Year: 2007


Clinical factors of long-term survival in patients with advanced lung cancer
Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up
Year: 2017

Stage IIIB and stage IV non-small cell lung cancers; responses to treatment and survival durations
Source: Eur Respir J 2004; 24: Suppl. 48, 302s
Year: 2004

The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival
Source: Eur Respir J 2007; 30: Suppl. 51, 280s
Year: 2007

Management of patients with non-small-cell lung cancer
Source: ERS Live 2007
Year: 2007

The treatment of stage IV non-small cell lung cancer with target therapies
Source: Annual Congress 2013 –Which treatment other than chemotherapy for stage IV NSCLC?
Year: 2013